HETERO LABS LTD V
GenericsHETERO LABS LTD V is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Neurology. Key products include LAMIVUDINE AND ZIDOVUDINE.
HETERO LABS LTD V's Key Drugs
HETERO LABS LTD V's core commercial portfolio centers on OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE AND OLMESARTAN MEDOXOMIL, EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, spanning Cardiovascular and Infectious Disease — its most strategically important drugs approved in the last 15 years.
Hypertension
Hypertension
HIV-1 infection
Hypertension
HETERO LABS LTD V's Recent FDA Approvals
New NDA/BLA approvals for HETERO LABS LTD V over the last two years — novel drugs only, excluding generics and label supplements.
HETERO LABS LTD V's Therapeutic Areas
HETERO LABS LTD V's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HETERO LABS LTD V's Top Competitors
HETERO LABS LTD V's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HETERO LABS LTD V Pipeline Snapshot
Active clinical trials for HETERO LABS LTD V across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (5)
Discontinued (2)
Company Info
- First Approval
- 2012-09-27
- Latest
- 2026-06-10
- Applications
- 82